GLP-1-based medications show increasing evidence of beneficial effects on heart failure outcomes in patients with preserved and possibly mildly reduced ejection fraction.
Do GLP-1-based medications improve heart failure-related outcomes in patients with heart failure, particularly those with preserved or mildly reduced ejection fraction?
GLP-1-based medications represent a promising therapeutic option for improving outcomes in patients with HFpEF and HFmrEF, leveraging the pathophysiological links between diabetes, obesity, and heart failure.
Glucagon-like Peptide 1 (GLP-1)-based medications have been extensively studied for the management of type 2 diabetes, obesity, chronic kidney disease, and atherosclerotic cardiovascular disease. More recently, their potential role in preventing and treating heart failure has gained increasing attention. Given the strong pathophysiological links among diabetes, obesity, and heart failure, GLP-1-based medications represent a promising therapeutic option to improve morbidity and mortality across these interconnected conditions. In this review, we summarise and discuss recent studies involving GLP-1-based medications that have reported on HF-related outcomes. There is increasing evidence that these medications have beneficial effects on HF outcomes in patients with heart failure with preserved ejection fraction and possibly in those with mildly reduced ejection fraction. The usefulness of GLP-1-based medications in reduced ejection fraction HF remains to be defined.
May 2026 publication; tied to SOUL trial media coverage; high shares in cardiology Twitter.
Lee et al. (Fri,) conducted a review in Heart failure with preserved or mildly reduced ejection fraction. GLP-1-based medications was evaluated. GLP-1-based medications show increasing evidence of beneficial effects on heart failure outcomes in patients with preserved and possibly mildly reduced ejection fraction.